Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)
An Open Label Extension Study Evaluating the Safety of Long Term Dosing of Romiplostim in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Subject completed a romiplostim study for the treatment of thrombocytopenia in subjects with MDS
- Subject has an Eastern Cooperative Oncology (ECOG) performance status of 0 to 2
- Subject had a platelet count ≤ 50 x 10^9/L since the final dose of investigational product in the parent study
- Subject or his/her legally acceptable representative provided written informed consent before any study-specific procedures were initiated
Exclusion Criteria
- Subject has been diagnosed with AML or has a blast count ≥ 10% by peripheral blood or bone marrow biopsy
- Subject has a prior history of leukemia
- Subject has a prior history of bone marrow or stem cell transplantation
- Subject has a prior malignancy (other than in situ cervical cancer, controlled prostate cancer, or basal cell cancer of the skin) unless treated with curative intent and without evidence of disease for ≥ 3 years before randomization
- Subject has active or uncontrolled infections
- Subject has unstable angina, congestive heart failure [New York Heart Association (NYHA) > class II], uncontrolled hypertension (diastolic > 100 mmHg), uncontrolled cardiac arrhythmia, or recent (within 1 year) myocardial infarction
- Subject has a history of arterial thrombosis (eg, stroke or transient ischemic attack) in the past year
- Subject has a history of venous thrombosis that currently requires anti-coagulation therapy
- Subject received interleukin (IL)-11 within 4 weeks of screening
- Subject previously received a thrombopoietic growth factor (other than romiplostim)
- Subject has a known hypersensitivity to any recombinant E coli-derived product (eg, Infergen®, Neupogen®, Somatropin, Actimmune)
- Subject is currently enrolled in investigational device or drug study(ies), has not yet completed at least 4 weeks since ending investigational device or drug study(ies) (other than parent romiplostim study), or subject is receiving other investigational agent(s)/device(s)
- Subject is of child-bearing potential and is evidently pregnant (eg, positive human chorionic gonadotropin [HCG] test) or is breast feeding
- Subject is not using adequate contraceptive precautions
- Subject has any kind of disorder that compromises his/her ability to give written informed consent (and does not have a legally acceptable representative) or is unable to comply with study procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Open Label Romiplostim (formerly AMG 531)
|
Subjects will begin the study at an initial dose of 750 µg. Except for:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall Summary of Adverse Events
Time Frame: During treatment period from first dose of IP to End of Study visit, on Average 56 Weeks .
|
During treatment period from first dose of IP to End of Study visit, on Average 56 Weeks .
|
|
Incidence of Antibody (AB) Formation
Time Frame: During treatment period from first dose of IP to End of Study visit, on Average 56 Weeks.
|
During treatment period from first dose of IP to End of Study visit, on Average 56 Weeks.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Weekly Bleeding Events Per 100 Subject Years
Time Frame: During the treatment period. The average duration of romiplostim exposure is 56 weeks.
|
During the time since the first dose of IP to the end of the treatment period.
A single bleeding event was defined as each individual bleeding episode that originated from a specific organ system (eg, gastrointestinal system or central nervous system).
A bleeding event that continued for more than 7 days was counted as separate events every eighth day.
|
During the treatment period. The average duration of romiplostim exposure is 56 weeks.
|
|
Platelet Transfusion Events Per 100 Subject Years
Time Frame: During the treatment period. The average duration of romiplostim exposure is 56 weeks.
|
During the time since the first dose of IP to the end of the treatment period.
A discrete platelet transfusion event was defined as any number of platelet transfusions administered within a 3-day period.
Platelet transfusions administered more than 3 days apart were counted as separate platelet transfusion events.
|
During the treatment period. The average duration of romiplostim exposure is 56 weeks.
|
|
Weeks With Platelet Response Per Year
Time Frame: During the treatment period. The average duration of romiplostim exposure is 56 weeks.
|
During the time since the first dose of IP to the end of the treatment period.
Platelet response was based on the modified IWG 2006 criteria (Cheson et al, 2006) and was defined as, in the absence of platelet transfusion: an absolute increase in platelet count of ≥ 30 x 10^9/L for a subject starting with a platelet count of ≥ 20 x 10^9/L; or an increase in platelet count from < 20 x 10^9/L to ≥ 20 x 10^9/L and by at least 100% in a subject that started with a platelet count < 20 x 10^9/L.
|
During the treatment period. The average duration of romiplostim exposure is 56 weeks.
|
|
Time to First Platelet Response
Time Frame: During treatment period. The average duration of romiplostim exposure is 56 weeks.
|
Time since first dose of IP to the first platelet response.
Platelet response was based on the modified IWG 2006 criteria (Cheson et al, 2006) and was defined as, in the absence of platelet transfusion: an absolute increase in platelet count of ≥ 30 x 10^9/L for a subject starting with a platelet count of ≥ 20 x 10^9/L; or an increase in platelet count from < 20 x 10^9/L to ≥ 20 x 10^9/L and by at least 100% in a subject that started with a platelet count < 20 x 10^9/L.
|
During treatment period. The average duration of romiplostim exposure is 56 weeks.
|
|
Duration of Platelet Response
Time Frame: During treatment period. The average duration of romiplostim exposure is 56 weeks.
|
Platelet response was based on the modified IWG 2006 criteria (Cheson et al, 2006) and was defined as, in the absence of platelet transfusion: an absolute increase in platelet count of ≥ 30 x 10^9/L for a subject starting with a platelet count of ≥ 20 x 10^9/L; or an increase in platelet count from < 20 x 10^9/L to ≥ 20 x 10^9/L and by at least 100% in a subject that started with a platelet count < 20 x 10^9/L.
|
During treatment period. The average duration of romiplostim exposure is 56 weeks.
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20060197
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.